PARP7/HDACs-IN-1

PARP7/HDACs-IN-1

• UNSPSC Description: PARP7/HDACs-IN-1 (compound 9l) is a dual-target inhibitor targeting PARP7/HDAC with anti-tumor activity. PARP7/HDACs-IN-1 inhibits different subtypes of PARPs and HDACs with IC50s of 83.3 nM (PARP1), 3.1 nM (PARP7), 35 nM (HDAC1), 30.3 nM (HDAC2), 35.4 nM (HDAC3), and 6.4 nM respectively. (HDAC6)[1]. br/[1].
• Target Antigen: HDAC; PARP
• Type: Reference compound
• Related Pathways: Cell Cycle/DNA Damage;Epigenetics
• Applications: Cancer-programmed cell death
• Field of Research: cancer
• Assay Protocol: https://www.medchemexpress.com/parp7-hdacs-in-1.html
• Solubility: 10 mM in DMSO
• Smiles: O=C1NN=CC(N[C@H](COCCC(N2CCN(CC2)C3=NC=C(C=N3)OCC4=CC=C(C=C4)/C=C/C(NO)=O)=O)C)=C1C(F)(F)F
• Molecular Weight: 646.62
• References & Citations: [1]Duan J L, et al. Design, Synthesis, and Structure–Activity Relationship of Novel Pyridazinone-Based PARP7/HDACs Dual Inhibitors for Elucidating the Relationship between Antitumor Immunity and HDACs Inhibition[J]. Journal of Medicinal Chemistry, 2024.
• Shipping Conditions: Room temperature
• Clinical Information: No Development Reported